Impax receives approval for anthrax anti-bacterial

Impax Laboratories, Inc., recently announced that it has received Food and Drug Administration approval for the company’s abbreviated new drug application for a generic version of Doryx, an anti-bacterial that can be used to treat anthrax victims.

The generic version of Doryx will be produced in 75 milligram and 100 milligram tablets. The company is preparing to conduct the launch through its generic division, Global Pharmaceuticals, according to

Doryx is a tetracycline-class anti-bacterial agent. It has been indicated for use to treat anthrax infections, including those that are from inhalation and post-exposure, as well as ricksettsial infections, sexually transmitted infections, respiratory tract infections, specific bacterial infections, ophthalmic infections.

It is also cleared as an alternative treatment for certain infections when penicillin is contraindicated, and as adjunctive therapy in acute intestinal amebiasis and severe acne, as well as in prophylaxis of malaria.

Impax Laboratories is a California-based pharmaceutical company that focuses predominantly on disorders related to the central nervous system. It prefers to apply its expertise in the area of developing differentiated, modified or control-release versions of currently marketed products.

Impax Laboratories maintains its commercial production base in Hayward, California, where it can produce 1.2 billion units annually. In addition, it has a packaging facility in Philadelphia, Pennsylvania, and runs another production facility in Taiwan. Its Taiwan center can produce 600 million units annually and remains ready to increase that number in the future.